Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Biopharmaceutical company reports second quarter 2005 results
August 15th, 2005
Nabi Biopharmaceuticals (NABI) announced that it has continued to build momentum toward commercialization of its lead product in development, StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), by increasing its investment in research and development in the second quarter to $19 million. In addition, the company continued to invest in the marketing, pricing and reimbursement activities to support the expected launch of StaphVAX in Europe in 2006. Funding for this increased level of investment was generated by the cash margin earned from sales of $26 million, including biopharmaceutical sales of $15 million, and from the use of cash from the balance...
Source: Pharma Business Week (2005-08-15)
|
